Fiscal Constraints Threaten Tenure At Medical Schools

A wave of anxiety is sweeping the nation's 125 medical schools. These schools and their affiliated teaching hospitals--the academic health centers where new doctors are minted and where cutting edge biomedical research and medicine is practiced--are being squeezed financially by cost-conscious health maintenance organizations. Managed care providers steer their members who need medical care to nonteaching hospitals where costs are lower or, when their members do see doctors at academic health c

Written byBilly Goodman
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

The ascendancy of managed care is upsetting a relationship that some call a key to the strength of American health care: the cross-subsidization of the teaching and research enterprises from patient care income. Most medical schools have depended on clinical income to support their teaching and research missions because, several administrators told The Scientist for this article, tuition, government research grants, and state funds do not cover the true costs of teaching and research. As clinical revenues to academic health centers decline--or threaten to--medical school administrators find themselves pressured to identify new, reliable sources of funding and to operate their centers more like a business. That has led to cost-cutting and, in some cases, mergers between academic health centers and other hospitals.

CERTAIN PLEASER: Boris Draznin, a professor of medicine at the University of Colorado, says that when existing faculty are exempted from changes in tenure, negotiations go much smoother. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies